Assessing potential of psilocybin for depressive disorders
Zofia Kozak, Matthew W Johnson, Scott T Aaronson
Expert Opinion on Investigational Drugs October 3, 2023 DOI: 10.1080/13543784.2023.2273493 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Review Peer reviewed |
|---|---|
| Population | Patients with depression, specifically those with treatment-resistant depression |
| Topics | Depression Psychedelic-assisted therapy Psilocybin |
| Keywords | Psilocybin, psychedelics Magic mushroom therapy Treatment-resistant depression trd Refractory depression |
| Citations | 10 |
| Key findings | Patients with treatment-resistant depression may be the most suitable candidates for psilocybin treatment at this time. |
Abstract
There is still much unknown regarding the risks of psilocybin treatment. When weighing the known risks and benefits of psilocybin treatment against those found in existing standards of care, among patients with depression, patients with treatment-resistant depression (TRD) may be the most suitable candidates for psilocybin treatment at this time.
Comparable studies
Other narrative reviews on psilocybin and psychedelic-assisted therapy, most cited first.
| Study | Year | Design | Participants |
|---|---|---|---|
| Psychedelic-Assisted Psychotherapy: A Paradigm Shift in Psychiatric Research and Development | 2018 | Review | |
| Novel psychopharmacological therapies for psychiatric disorders: psilocybin and MDMA. | 2016 | Review | |
| Systematized Review of Psychotherapeutic Components of Psilocybin-Assisted Psychotherapy | 2021 | Systematized review | |
| The Emerging Field of Psychedelic Psychotherapy. | 2022 | Review | |
| Experience of Music Used With Psychedelic Therapy: A Rapid Review and Implications Participants in psychedelic therapy research aged 18–69 with varied backgrounds | 2020 | Rapid review | n = 180 |